Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. has a promising outlook due to its robust pipeline of seven adeno-associated virus (AAV)-based programs targeting a range of inherited retinal diseases, which could lead to significant advancements in gene therapies. Recent data indicate a substantial improvement in visual acuity among treated patients, with one-year post-treatment results showing a notable increase in light sensitivity scores, suggesting the therapies' potential long-lasting efficacy. Furthermore, the company's positive terminal growth rate and the broad scope of its preclinical assets position Opus Genetics favorably for future development and financial performance.

Bears say

Opus Genetics Inc. has sustained significant losses since its inception, which raises concerns about its financial viability and ability to attract further investment. The company faces substantial market competition from emerging therapies that target similar inherited retinal diseases, posing risks to its market penetration and pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, or commercialization timelines could result in extended development periods and increasing costs, further complicating the company's path to profitability.

Opus Genetics (IRD) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Apr 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.